Real-world evidence on multiple myeloma treated in 2013-2019 in the Hospital District of Helsinki and Uusimaa, Finland - Supplementary material

Supplementary figure 1. The annual incidence of stem cell transplantation (SCT) eligible multiple myeloma patients with 95% confidence intervals in 2013–2018 estimated as the number of SCT procedures (only the first SCT procedure per patient considered) among initiated first-line immunochemotherapies in each year. Both incidence per each year (solid line) and mean incidence (dashed line; Mann Kendall trend test p-value, 0.71) are provided.Supplementary figure 2. All-cause health care resource use per patient year (PPY; with 95% confidence intervals) in multiple myeloma patients with and without record(s) on stem cell transplantation (SCT). Patients diagnosed and treated in the Hospital District of Helsinki and Uusimaa, Finland, in 2013–2019 were included.Supplementary figure 3. Cox proportional multivariable hazards models assessing the effect of the patient characteristics (age, sex, and Charlson Comorbidity Index, CCI) at diagnosis and diagnosis year on the overall survival.Supplementary table 1. Multiple myeloma medications and respective codes utilized in the studySupplementary table 2. ICD-10 diagnoses recorded five years prior to the first ICD-10 record on multiple myeloma as a diagnosis, among 509 adult patients diagnosed and treated with immunochemotherapy in 2013–2019 in the Hospital District of Helsinki and Uusimaa, Finland.Supplementary table 3. The number of multiple myeloma patients with each type of induction/reinduction treatment in the first three lines of immunochemotherapy (ICT; for the abbreviations, see the Supplementary table 1). ICTs started in 2013–2016 (“Pre 2017”) and 2017–2019 (“Post 2017”) are separately reportedSupplementary methods

补充图1。本图展示了2013-2018年符合造血干细胞移植（stem cell transplantation, SCT）指征的多发性骨髓瘤患者的年发病率及95%置信区间，该发病率以每年启动一线免疫化疗的患者中接受SCT操作的人数计算（仅统计每位患者的首次SCT操作）。图中同时呈现了各年度发病率（实线）与平均发病率（虚线；曼-肯德尔趋势检验P值为0.71）。
补充图2。本图展示了芬兰赫尔辛基与乌西马医院区2013-2019年确诊并接受治疗的多发性骨髓瘤患者中，伴与不伴造血干细胞移植（SCT）记录的患者每患者年（PPY, per patient year）全因医疗资源使用情况及95%置信区间。
补充图3。本图为考克斯比例多变量风险模型，用于评估确诊时的患者特征（年龄、性别与查尔森合并症指数（Charlson Comorbidity Index, CCI））以及确诊年份对总生存期的影响。
补充表1。本研究中使用的多发性骨髓瘤治疗药物及对应编码。
补充表2。针对芬兰赫尔辛基与乌西马医院区2013-2019年确诊并接受免疫化疗的509例成年患者，本补充表列出了以多发性骨髓瘤为诊断的首次ICD-10记录前5年所记录的ICD-10诊断条目。
补充表3。免疫化疗（immunochemotherapy, ICT，缩写详见补充表1）前3线治疗中，接受各类诱导/再诱导治疗的多发性骨髓瘤患者人数。本研究分别报告了2013-2016年（“2017年前”）与2017-2019年（“2017年后”）启动的免疫化疗方案。
补充方法